Apolipoprotein E gene polymorphism and the risk of cervical myelopathy in patients with chronic spinal cord compression

Spine

Volumn 33, Issue 5, 2008, Pages 497-502

  Setzer, Matthias ^a,b   Hermann, Elvis ^a   Seifert, Volker ^a   Marquardt, Gerhard ^a  

^a GOETHE UNIVERSITY   (Germany)

^b Zentrum der Neurologie und Neurochirurgie   (Germany)

Author keywords

APOE genotype; APOE polymorphism; Cervical spondylotic myelopathy; Chronic spinal cord compression; Spinal canal stenosis

Indexed keywords

APOLIPOPROTEIN E; APOLIPOPROTEIN E2; APOLIPOPROTEIN E3; APOLIPOPROTEIN E4;

ADULT; ARTICLE; CERVICAL MYELOPATHY; CLINICAL EVALUATION; DISEASE ASSOCIATION; DNA POLYMORPHISM; FEMALE; HUMAN; HYPOTHESIS; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; NEUROLOGIC EXAMINATION; POLYACRYLAMIDE GEL ELECTROPHORESIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION MAPPING; RISK FACTOR; SPINAL CORD COMPRESSION; UNIVARIATE ANALYSIS; VERTEBRAL CANAL STENOSIS; AGED; CERVICAL SPINE; CHRONIC DISEASE; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETICS; GENOTYPE; MIDDLE AGED; PROSPECTIVE STUDY; SPONDYLOSIS;

ADULT; AGED; AGED, 80 AND OVER; APOLIPOPROTEIN E2; APOLIPOPROTEIN E3; APOLIPOPROTEIN E4; APOLIPOPROTEINS E; CERVICAL VERTEBRAE; CHRONIC DISEASE; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PROSPECTIVE STUDIES; RISK FACTORS; SPINAL CORD COMPRESSION; SPINAL OSTEOPHYTOSIS;

EID: 41049088854     PISSN: 03622436     EISSN: 15281159     Source Type: Journal    
DOI: 10.1097/BRS.0b013e3181657cf7     Document Type: Article

References (56)

1. Arnold JGJ. The clinical manifestations of spondylochondrosis (spondylosis) of the cervical spine. Ann Surg 1955;141:872-89.
2. Burrows EH. The sagittal diameter of the spinal canal in cervical spondylosis. Clin Radiol 1963;14:77-86.
3. Adams CB, Logue V. Studies in cervical spondylotic myelopathy. II. The movement and contour of the spine in relation to the neural complications of cervical spondylosis. Brain 1971;94:568-86.
4. Murone I. The importance of the sagittal diameter of the cervical spinal canal in relation to spondylosis and myelopathy. J Bone Joint Surg Br 1976;56:30-6.
5. Edwards WC, LaRocca H. The developmental segmental diameter of the cervical spinal canal in patients with cervical spondylosis. Spine 1983;8:20-7.
6. Parke WW. Correlative anatomy of cervical spondylotic myelopathy. Spine 1988;13:831-7.
7. Fehlings MG, Skaff GA. Review of the pathophysiology of cervical spondylotic myelopathy with insights for potential novel mechanisms drawn from traumatic spinal cord injury. Spine 1998;23:2730-7.
8. Agrawal SK, Fehlings MG. Mechanisms of secondary injury to spinal cord axons in vitro: role of Na+, Na(+)-K(+)-ATPase, the Na(+)-H+ exchanger, and the Na(+)-Ca2+ exchanger. J Neurosci 1996;16:545-52.
9. Gurney ME. The use of transgenic mouse models of amyotrophic lateral sclerosis in preclinical drug studies. J Neurol Sci 1997;152(suppl):67- 73.
10. Bracken MB, Shepard MJ, Collins WF, et al. A randomized, controlled trial of methylprednisolone or naloxone in the treatment of acute spinal-cord injury. Results of the second national acute spinal cord injury study (see comments). N Engl J Med 1990;322:1405-11.
11. Bracken MB, Shepard MJ, Holford TR, et al. Administration of methylprednisolone for 24 or 48 hours or tirilazad mesylate for 48 hours in the treatment of acute spinal cord injury. Results of the third national acute spinal cord injury-randomized controlled trial. National acute spinal cord injury study. JAMA 1997;277:1597-604.
12. Crowe MJ, Bresnahan JC, Shuman SL, et al. Apoptosis and delayed degeneration after spinal cord injury in rats and monkeys. Nat Med 1997;3:73-6.
13. Liu XZ, Xu XM, Hu R, et al. Neuronal and glial apoptosis after traumatic spinal cord injury. J Neurosci 1997;17:5395-406.
14. Shuman SL, Bresnahan JC, Beattie MS. Apoptosis of microglia and oligodendrocytes after spinal cord contusion in rats. J Neurosci Res 1997;50:798-808.
15. Ball J, El Gammal T, Popham M. A possible genetic factor in cervical spondylosis. Br J Radiol 1969;42:9-16.
16. Mahley RW. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science 1988;240:622-30.
17. Das HK, McPherson J, Bruns GA, et al. Isolation, characterization, and mapping to chromosome 19 of the human apolipoprotein E gene. J Biol Chem 1985;260:6240-7.
18. Zannis VI, Breslow JL, Utermann G, et al. Proposed nomenclature of apoE isoproteins, apoE genotypes, and phenotypes. J Lipid Res 1982;6:911-14.
19. Weisgraber KH, Rall SC Jr, Mahley RW. Human E apoprotein heterogeneity. Cysteine-arginine interchanges in the amino acid sequence of the apo-E isoforms. J Biol Chem 1981;256:9077-83.
20. Rall SC Jr, Weisgraber KH, Mahley RW. Human apolipoprotein E. The complete amino acid sequence. J Biol Chem 1982;257:4171-8.
21. Strittmatter WJ, Saunders AM, Schmechel D, et al. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci USA 1993;90:1977-81.
22. Saunders AM, Strittmatter WJ, Schmechel D, et al. Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease. Neurology 1993;43:1467-72.
23. Ueki A, Kawano M, Namba Y, et al. A high frequency of apolipoprotein E4 isoprotein in Japanese patients with late-onset nonfamilial Alzheimer's disease. Neurosci Lett 1993;163:166-8.
24. Poirier J, Davignon J, Bouthillier D, et al. Apolipoprotein E polymorphism and Alzheimer's disease. Lancet 1993;342:697-9.
25. Huq L, McLachlan T, Hammer HM, et al. An increased incidence of apolipoprotein E2/E2 and E4/E4 in retinitis pigmentosa. Lipids 1993;28:995-8.
26. Drory VE, Birnbaum M, Korczyn AD, et al. Association of APOE epsilon4 allele with survival in amyotrophic lateral sclerosis. J Neurol Sci 2001;190:17-20.
27. Liaquat I, Dunn LT, Nicoll JA, et al. Effect of apolipoprotein E genotype on hematoma volume after trauma. J Neurosurg 2002;96:90-6.
28. Lanterna LA, Rigoldi M, Tredici G, et al. APOE influences vasospasm and cognition of noncomatose patients with subarachnoid hemorrhage. Neurology 2005;64:1238-44.
29. Teasdale GM, Nicoll JA, Murray G, et al. Association of apolipoprotein E polymorphism with outcome after head injury. Lancet 1997;350:1069-71.
30. Leung CH, Poon WS, Yu LM, et al. Apolipoprotein e genotype and outcome in aneurysmal subarachnoid hemorrhage. Stroke 2002;33:548-52.
31. Niskakangas T, Ohman J, Niemela M, et al. Association of apolipoprotein E polymorphism with outcome after aneurysmal subarachnoid hemorrhage: a preliminary study. Stroke 2001;32:1181-4.
32. Tang J, Zhao J, Zhao Y, et al. Apolipoprotein E epsilon4 and the risk of unfavorable outcome after aneurysmal subarachnoid hemorrhage. Surg Neurol 2003;60:391-6.
33. Benzel EC, Lancon J, Kesterson L, et al. Cervical laminectomy and dentate ligament section for cervical spondylotic myelopathy. J Spinal Disord 1991;4:286-95.
34. Wenham PR, Price WH, Blundell G. Apolipoprotein E genotyping by one-stage PCR. Lancet 1991;337:1158-9.
35. Shrout PE, Fleiss JL. Intraclass correlations: uses in assessing rater reliability. Psychol Bull 1979;2:420-8.
36. Schlag B, Oswald B, Kopitzsch S, et al. Frequency distribution of apolipoprotein E isoforms in healthy probands. Z Med Lab Diagn 1987;28:410-14.
37. Henderson FC, Geddes JF, Vaccaro AR, et al. Stretch-associated injury in cervical spondylotic myelopathy: new concept and review. Neurosurgery 2005;56:1101-13.
38. Pitas RE, Boyles JK, Lee SH, et al. Astrocytes synthesize apolipoprotein E and metabolize apolipoprotein E-containing lipoproteins. Biochim Biophys Acta 1987;917:148-61.
39. Swanson LW, Simmons DM, Hofmann SL, et al. Localization of mRNA for low density lipoprotein receptor and a cholesterol synthetic enzyme in rabbit nervous system by in situ hybridization. Proc Natl Acad Sci USA 1988;85:9821-5.
40. Elshourbagy NA, Liao WS, Mahley RW, et al. Apolipoprotein E mRNA is abundant in the brain and adrenals, as well as in the liver, and is present in other peripheral tissues of rats and marmosets. Proc Natl Acad Sci USA 1985;82:203-7.
41. Boyles JK, Pitas RE, Wilson E, et al. Apolipoprotein E associated with astrocytic glia of the central nervous system and with nonmyelinating glia of the peripheral nervous system. J Clin Invest 1985;76:1501-13.
42. Murakami M, Ushio Y, Morino Y, et al. Immunohistochemical localization of apolipoprotein E in human glial neoplasms. J Clin Invest 1988;82:177-88.
43. Mayeux R, Ottman R, Maestre G, et al. Synergistic effects of traumatic head injury and apolipoprotein-epsilon 4 in patients with Alzheimer's disease. Neurology 1995;45:555-7.
44. Slooter AJ, Tang MX, van Duijn CM, et al. Apolipoprotein E epsilon4 and the risk of dementia with stroke. A population-based investigation. JAMA 1997;277:818-21.
45. Resnick DK, Schmitt C, Miranpuri GS, et al. Molecular evidence of repair and plasticity following spinal cord injury. Neuroreport 2004;15:837-9.
46. Seitz A, Kragol M, Aglow E, et al. Apolipoprotein E expression after spinal cord injury in the mouse. J Neurosci Res 2003;71:417-26.
47. Seitz A, Gourevitch D, Zhang XM, et al. Sense and antisense transcripts of the apolipoprotein E gene in normal and ApoE knockout mice, their expression after spinal cord injury and corresponding human transcripts. Hum Mol Genet 2005;14:2661-70.
48. Haasdijk ED, Vlug A, Mulder MT, et al. Increased apolipoprotein E expression correlates with the onset of neuronal degeneration in the spinal cord of G93A-SOD1 mice. Neurosci Lett 2002;335:29-33.
49. Buttini M, Orth M, Bellosta S, et al. Expression of human apolipoprotein E3 or E4 in the brains of Apoe-/- mice: isoform-specific effects on neurodegeneration. J Neurosci 1999;19:4867-80.
50. Corder EH, Saunders AM, Risch NJ, et al. Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nat Genet 1994;7:180-4.
51. Talbot C, Lendon C, Craddock N, et al. Protection against Alzheimer's disease with apoE epsilon 2. Lancet 1994;343:1432-3.
52. Kadanka Z, Bednarik J, Vohanka S, et al. Conservative treatment versus surgery in spondylotic cervical myelopathy: a prospective randomised study. Eur Spine J 2000;9:538-44.
53. Morio Y, Teshima R, Nagashima H, et al. Correlation between operative outcomes of cervical compression myelopathy and mri of the spinal cord. Spine 2001;26:1238-45.
54. Suri A, Chabbra RP, Mehta VS, et al. Effect of intramedullary signal changes on the surgical outcome of patients with cervical spondylotic myelopathy. Spine J 2003;3:33-45.
55. Bednarik J, Kadanka Z, Dusek L, et al. Presymptomatic spondylotic cervical cord compression. Spine 2004;29:2260-9.
56. Matsunaga S, Sakou T, Taketomi E, et al. Clinical course of patients with ossification of the posterior longitudinal ligament: a minimum 10-year cohort study. J Neurosurg 2004;100 (3 suppl Spine):245- 8.-